You are on page 1of 9

Nutrition in Clinical Practice

Waist Circumference Measurement in Clinical Practice

Rosane Ness-Abramof and Caroline M. Apovian
Nutr Clin Pract 2008 23: 397
DOI: 10.1177/0884533608321700
The online version of this article can be found at:

Published by:

On behalf of:

The American Society for Parenteral & Enteral Nutrition

Additional services and information for Nutrition in Clinical Practice can be found at:
Email Alerts:

>> Version of Record - Aug 5, 2008

What is This?

Downloaded from at NATIONAL SUN YAT-SEN UNIV on August 22, 2014

Invited Review

Waist Circumference Measurement

in Clinical Practice

Nutrition in Clinical Practice

Volume 23 Number 4
August 2008 397-404
2008 American Society for
Parenteral and Enteral Nutrition
hosted at

Rosane Ness-Abramof, MD1; and Caroline M. Apovian, MD2

Financial disclosure: none declared.
The obesity epidemic is a major public health problem worldwide. Adult obesity is associated with increased morbidity and
mortality. Measurement of abdominal obesity is strongly associated with increased cardiometabolic risk, cardiovascular events,
and mortality. Although waist circumference is a crude measurement, it correlates with obesity and visceral fat amount, and
is a surrogate marker for insulin resistance. A normal waist circumference differs for specific ethnic groups due to different
cardiometabolic risk. For example, Asians have increased cardiometabolic risk at lower body mass indexes and with lower
waist circumferences than other populations. One criterion for

the diagnosis of the metabolic syndrome, according to different

study groups, includes measurement of abdominal obesity
(waist circumference or waist-to-hip ratio) because visceral adipose tissue is a key component of the syndrome. The waist circumference measurement is a simple tool that should be widely
implemented in clinical practice to improve cardiometabolic
risk stratification. (Nutr Clin Pract. 2008;23:397-404)

International Diabetes Federation (IDF).7 According to

the 2003-2004 National Health and Nutrition
Examination Survey (NHANES), more than 50% of U.S.
adults can be described as having abdominal obesity.8
This review summarizes the scientific data linking an
increased WC to increased cardiovascular, DM, and mortality risk and the importance of its assessment in clinical

Keywords: waist-hip ratio; body weight; body weight changes;

obesity; metabolic syndrome X; cardiovascular diseases; diabetes

he current obesity epidemic poses a global concern

because of its related health problems. Obesity
increases the risk for diabetes mellitus (DM), hypertension, coronary heart disease, dyslipidemia, certain
cancers, and obstructive sleep apnea, among other
comorbidities.1-3 Although overweight and obesity are
associated with an increased risk for DM and cardiovascular disease, the pattern of fat distribution is also important in risk stratification.4 Intra-abdominal (visceral) fat
deposition is linked to an increased risk for developing
DM and cardiovascular disease compared with a more
peripheral (subcutaneous) fat distribution. The accurate
measurement of visceral fat requires the use of advanced
methods not available in clinical practice such as computed
tomography (CT) or magnetic resonance imaging (MRI).
On the other hand, a simple measurement of waist circumference (WC) is strongly correlated with risk for DM
and cardiovascular disease.5 Increased WC is one of the
diagnostic criteria for the metabolic syndrome, according
to the National Cholesterol Education Program (NCEP)
Adult Treatment Panel III (ATP III),6 and is essential for
the diagnosis of the metabolic syndrome, according to the

Measurement of Body Adiposity

Body fat is composed of cells that contain triglyceride
stores. Body fat can be divided into 2 main compartments: subcutaneous and intra-abdominal. Fat may also
accumulate at ectopic sites such as muscle, including the
heart, pancreas, and liver.9,10
There are many ways to measure total body fat; traditionally, the gold standard for body fat estimation has
been hydrodensitometry (underwater weighing), based on
the fact that fat tissue is less dense than muscle and bone.
Dual-energy X-ray absortiometry (DXA) is another
method for evaluating body composition. These 2 methods are used mainly in research and are not readily available for clinical practice or epidemiological studies.
Imaging studies such as CT, MRI, and DXA may evaluate fat partitioning, normally with most of the fat
located in the subcutaneous space and less in the visceral
space and most of the visceral fat located in the intraabdominal space (intraperitoneal and retroperitoneal).
The amount of visceral fat is influenced by gender, age,

From the 1Endocrine Unit, Meir Hospital, Kfar Saba, Sackler

School of Medicine, Tel Aviv University, Tel Aviv, Israel, and
Division of Endocrinology, Diabetes, Nutrition and
Metabolism, Boston Medical Center, Boston University School
of Medicine, Boston, Massachusetts.
Address correspondence to: Caroline M. Apovian, MD, Center
for Nutrition and Weight Management, Boston Medical Center,
88 East Newton Street Robinson Bldg, Suite 4400, Boston, MA
02118; e-mail:


Downloaded from at NATIONAL SUN YAT-SEN UNIV on August 22, 2014


Nutrition in Clinical Practice / Vol. 23, No. 4, August 2008

race/ethnicity, physical activity, and total adiposity.11

Computed tomography and MRI are now the gold standards for the evaluation of the abdominal subcutaneous
and visceral adipose tissue. A single slice at the L4-L5
intervertebral level is used to measure the amount of fat,
expressed in cubic cm.11 It is possible that the intramuscular fat is correlated more to the visceral fat than the
subcutaneous fat.12 The deleterious effect of fat deposition in the liver is well known. Nonalcoholic steatohepatitis (NASH) is a common disorder known to correlate
with insulin resistance, increased triglyceride production
leading to an atherogenic dyslipidemia, type 2 DM, and
cirrhosis. Intrahepatic fat deposition can be evaluated
easily by ultrasound (US) of the liver, but US is not very
sensitive in the earlier stages of steatosis, and it does not
quantify lipid content. Computed tomography is used to
measure hepatic steatosis, whereas the most accurate tool
for quantifying lipid storage in the hepatocytes is
achieved by nuclear magnetic resonance (NMR).13,14
Pancreatic fat infiltration is also associated with
decreased insulin secretion and -cell apoptosis.15

Anthropometric Measurements
Body Mass Index
Body mass index (BMI), as weight in kg divided by the
square of the height in meters (or weight in pounds multiplied by 703, then divided by height in inches), is an
easy way to calculate body fatness and is widely used in
clinical practice. Both the World Health Organization
(WHO) task force and the National Institutes of Health
(NIH) guidelines stipulate normal, overweight, and obesity cutoffs according to BMI. A BMI between 18.5 and
24.9 kg/m2 is considered normal, between 25 and 29.9
kg/m2 is overweight, and >30 kg/m2 is obese (Table 1).16,17
Because these cutoffs are arbitrary, there is some dispute whether normal weight should be defined as a BMI
of < 25 kg/m2. There has been an increase in the prevalence of DM and mortality with increasing BMI in
patients within normal range.18,19 This trend may be
explained by the pattern of fat distribution, with a more
central and particularly visceral fat accumulation being
associated with increased risk for DM and cardiovascular
disease; when added to BMI in patients with a BMI
between 25 and 35 kg/m2, this improves health risk assessment.20 Recent data failed to show an increase in mortality in overweight individuals compared with individuals of
normal weight, possibly due to improved cardiovascular
risk management, whereas obese and underweight individuals had higher mortality rates.21 The association
between increased gluteofemoral adipose tissue and cardiovascular risk is a much weaker one.22,23 Another pitfall
of relying on BMI alone is that muscular patients may

Table 1.

Classifications for Body Mass Index (BMI)

Normal weight
Obesity (class 1)
Obesity (class 2)
Extreme obesity (class 3)

<18.5 kg/m2
18.5-24.9 kg/m2
25-29.9 kg/m2
30-34.9 kg/m2
35-39.9 kg/m2
>40 kg/m2

Adapted from the National Institutes of Health. The Practical

Guide: Identification, Evaluation and Treatment of Overweight
and Obesity in Adults. Bethesda, MD: National Institutes of
Health; 2000.

have relatively high BMIs but low fat mass, and in the elderly, BMI may underestimate fat mass due to a decrease in
lean body mass.24-26

Waist Circumference
As mentioned earlier, body fat distribution is an important risk factor for obesity-related disease. Increased
visceral adipose tissue (also called central or abdominal
fat) is associated with increased risk for cardiometabolic
Precise measurement of the visceral fat component is
expensive and not feasible in clinical practice. Therefore,
WC is used as a surrogate marker of abdominal fat mass.
WC correlates with subcutaneous and visceral fat mass
and is related to increased cardiometabolic risk.20,27 A
WC >40 inches (102 cm) in men and >35 inches (88 cm)
in women is considered to confer an increased cardiometabolic risk. These WC cutoffs were derived from
Caucasian men and women living in the Netherlands to
correlate with WC values associated with a BMI 30
kg/m2, therefore identifying subjects who should be
advised to lose weight.28,29 The National Heart, Lung, and
Blood Institute (NHLBI) recommended measuring WC
along with BMI to assess patient risk stratification in subjects with a BMI between 25 and 35 kg/m2. Although not
incorporated in the guidelines, a comment recommends
measuring WC even in patients with normal BMI to
improve risk stratification.16 The cutoffs for normal WC
chosen by the NHLBI are as mentioned earlier: WC >40
inches (102 cm) in men and >35 inches (88 cm) in
women, independent of BMI or ethnicity. According to
the NHANES III, 1% of men and 14% of women with a
normal BMI had a high WC, and in the overweight range
(BMI between 25 and 29.9 kg/m2), 25% of men and
almost 70% of women had a high WC.11 Shen et al30 evaluated BMI, WC, and percent fat measured by DXA in
1010 healthy white and African American men and
women. WC had the strongest association with health
risk, followed by BMI and percent fat.

Downloaded from at NATIONAL SUN YAT-SEN UNIV on August 22, 2014

Waist Circumference Measurement / Ness-Abramof, Apovian


Waist-to-Hip Ratio
Waist-to-hip ratio (WHR) is a common anthropometric index
used to assess abdominal obesity. The WHO included a high
WHR defined as a ratio >0.9 in men and >0.85 in women
as a criterion for diagnosing the metabolic syndrome.31 A
high WHR has been associated in epidemiological studies
with increased cardiovascular and DM risk.32,33 Because
both WHR and WC are measures of abdominal adiposity,
they both correlate with increased risk of cardiovascular
events. Some studies have found that WHR is a more accurate tool to diagnose patients with a higher cardiovascular
risk compared with WC and BMI,34 whereas other studies
have found a better correlation of cardiometabolic risk with
WC compared with WHR, particularly in women.35 The
Interheart Study, an epidemiological, retrospective case
control study in different populations, included more than
27, 000 people from 52 countries, with the study variable
being a history of myocardial infarction (MI). In this study,
BMI, WC, and WHR were all highly significantly associated with the risk for MI, but WHR was the strongest
anthropometric predictor of MI in men and women, independent of other risk factors or BMI category.36

How Should Waist

Circumference Be Measured?
Different anatomic landmarks used to measure WC
include the midpoint between the lowest rib and the iliac
crest, the umbilicus, the narrowest or widest WC, just
below the lowest rib, and just above the iliac crest. The
NHLBI practical guide recommends measuring just
above the iliac crest.16 WC measurement should be done
with the patient standing, bare midriff, after the patient
exhales, with both feet touching and arms hanging freely.
The measuring tape should be made of a material that is
not easily stretched; it should be placed perpendicular to
the long axis of the body and horizontal to the floor and
applied with tension, but it should not put pressure on
the abdominal wall (Figure 1).
A recent systematic review by Ross et al37 evaluated
whether the site of WC measurement influenced its relationship to morbidity and mortality. The most commonly
used landmarks were the minimal waist (33%), the midpoint between the lowest rib and the iliac crest (26%),
and the umbilicus (27%). According to their review, WC
protocol did not influence outcome concerning all-cause
and cardiovascular disease (CVD) mortality, CVD, and
DM. Therefore, it seems that the site of measurement
does not influence clinical outcome.

Visceral Adipose Tissue

Adipose tissue is now viewed as an active endocrine organ
and not merely as an energy depot.38 The visceral adipose

Figure 1. Measuring tape position for waist circumference measurement. Reproduced with permission from the National Heart,
Lung, and Blood Institute as a part of the National Institutes of
Health and the U.S. Department of Health and Human Services.
Available at

tissue (VAT) accounts for approximately 15% of total body

fat in the lean subject and includes the intraperitoneal
(mesenteric and omental) fat, which drains into the portal
circulation, and retroperitoneal fat, which drains into the
systemic circulation.39 There is a correlation between BMI
and WC with total adipose tissue mass, but WC has a
higher correlation with VAT than BMI alone.
Because the WC measures the subcutaneous abdominal tissue (SAT) and the VAT, it is not possible to discern
between the 2 compartments when measuring WC
(Figure 2).
The etiology of increased cardiometabolic risk in
patients with increased VAT is not known, but there are
many theories on the subject. Increased levels of free fatty
acids (FFAs) due to obesity and to increased VAT worsen
insulin resistance. The VAT is more insulin resistant, fueling
the hyperlipolytic state and worsening insulin resistance.
Although the VAT drains into the portal vein, most of the
FFA drained to the liver is derived from upper body non-VAT
fat.40 The increase in VAT mass possibly reflects the lack of
capacity of the subcutaneous tissue to store the energy
excess that accumulates in the liver, muscle, and pancreas,
worsening insulin resistance.10 Numerous cytokines are
secreted from the adipose tissue, including proinflammatory
molecules such as interleukin-6 (IL-6) and tumor necrosis
factor (TNF-). Plasma levels of C-reactive protein

Downloaded from at NATIONAL SUN YAT-SEN UNIV on August 22, 2014


Nutrition in Clinical Practice / Vol. 23, No. 4, August 2008

Figure 2. Computed tomography scans from 2 subjects with

comparable body mass index. Subcutaneous fat is shown in
black under the skin and visceral fat area (VFA) in white. Scans
were made at the L4-L5 level. Reproduced with permission
from Tchernof A, Desprs JP. Obesity and lipoprotein metabolism. In: Kopelman PG, ed. Clinical Obesity. London: Blackwell
Science Ltd; 1998:176204.

(CRP), an inflammatory factor produced by the liver and

known to correlate with atherosclerosis, are increased in
patients with visceral obesity.41,42 It has been recently
shown that the adipose tissue is infiltrated by
macrophages, contributing to the inflammatory
process.43,44 Adiponectin, a protein derived from the adipose tissue, is known to improve insulin sensitivity and may
protect against atherosclerosis.45,46 Adiponectin levels are
decreased in obesity and in viscerally obese patients.46,47
Another contributing factor may be local generation of cortisol from cortisone due to increased activity of 11 hydroxysteroid dehydrogenase in the VAT, which may
further increase fat deposition, worsen insulin resistance,
and increase cardiometabolic risk.48

The Metabolic Syndrome

The metabolic syndrome consists of a cluster of risk factors strongly associated with an increased risk for atherosclerotic cardiovascular disease (ASCVD) and type 2 DM.
The metabolic risk factors consist of a specific pattern of
hyperlipidemia (elevated serum levels of triglycerides and
apolipoprotein B, small low-density lipoprotein [LDL]
particles, and low serum high-density lipoprotein [HDL]
cholesterol levels), elevated blood pressure, elevated
plasma glucose concentration, a proinflammatory state,
and a prothrombotic state.6,49 Possibly the most important
risk factors for the development of the syndrome are
abdominal obesity and insulin resistance.
The NCEP ATP III held in 2001 provided diagnostic
criteria for the metabolic syndrome that could be easily
implemented in clinical practice. These criteria include
WC, blood pressure measurements, and serum levels of

triglycerides, HDL-C, and fasting glucose. The criteria

were further updated in 2005 by an executive summary by
the American Heart Association and NHLBI. One change
in the diagnostic criteria is a decrease in normal serum
glucose values to < 100 mg/dL instead of < 110 mg/dL,
and although WC cutoffs were not changed, there is a
recommendation that some white, black, and Hispanic
adults with marginally increased WC (e.g., 94-101 cm
[37-39 in] in men and 80-87 cm [31-34 in] in women)
may benefit from changes in lifestyle, similar to subjects
with higher WC and that a lower cutoff for WC (90 cm
[35 in] in men and 80 cm [31 in] in women) appears to
be appropriate for Asian Americans because this population is more prone to insulin resistance.
The IDF has adopted the same diagnostic criteria for
the metabolic syndrome but proposed an adaptation to
WC according to ethnic group, due to different risk in different populations. According to the IDF criteria, an
increased WC is essential for the diagnosis of the metabolic syndrome because it incorporates both insulin
resistance and abdominal obesity. The presence of 2 other
criteria is required for the diagnosis of the metabolic syndrome.7,50 The WHO criteria require a diagnosis of
insulin resistance (glucose intolerance, impaired glucose
tolerance [IGT], or DM and/or insulin resistance measured under hyperinsulinemic euglycemic conditions).
Table 2 compared the different criteria required for the
diagnosis according to the 3 different groups.
There has been some dispute whether the metabolic
syndrome can be called a syndrome or if it adds to risk
stratification of patients beyond the regular risk factors
(eg, hyperlipidemia, hypertension, DM).51 Because obesity is the main culprit for the epidemic proportion of the
metabolic syndrome, those in favor of the definition point
out that it is more important to focus on lifestyle changes
that may improve all components of the syndrome instead
of on each individual risk factor.52

Waist Circumference
and Type 2 Diabetes
The diabetes epidemic is closely linked to the obesity epidemic.53 In the Nurses Health Study, increases in BMI
within normal range were associated with a 4-fold risk of
developing type 2 DM (women with BMI <22 kg/m2 vs
women with BMI 23-25 kg/m2).18 The relationship
between WC and DM is very strong. WC is a stronger
predictor of DM than is BMI, and it is independent of traditional risk factors such as hypertension, lipoproteins,
and glucose levels.11 In the International Day for the
Evaluation of Abdominal Obesity (IDEA) study, which
included 69,409 subjects from 63 countries who consulted a primary care physician, BMI and particularly WC
were strongly linked to DM.54

Downloaded from at NATIONAL SUN YAT-SEN UNIV on August 22, 2014

Waist Circumference Measurement / Ness-Abramof, Apovian

Table 2.
Study Group
Diagnostic criteria

Metabolic Syndrome Definitions

Glucose intolerance, IGT,
or DM and/or insulin
resistance together with
2 of the following:

Fasting plasma glucose

Serum triglycerides
Serum HDL-cholesterol



150 mg/dL
Men: <35 mg/dL
Women: <39 mg/dL
140/90 mm Hg
Men: waist-hip ratio >0.9
Women: waist-hip ratio >0.85
and/or BMI 30 kg/m2



3 of the following
risk factors:

>100 mg/dL
(or diagnosed DM)
150 mg/dL
Men: <40 mg/dL
Women: <50 mg/dL
130/85 mm Hg
Men: waist circumference
>40 in (102 cm)
Women: waist circumference
>35 in (88 cm)

Central obesity
(waist circumference)
94 cm for Europid men
80 cm for Europid women
Ethnicity-specific values for
other groupsa
Plus presence of 2
of the following:
100 mg/dL
(or diagnosed DM)
150 mg/dL
Men: <40 mg/dL
Women: <50 mg/dL
130/85 mm Hg

Albumin/creatinine >30 mg/g

or urinary albumin
excretion rate 20 g/min

DM, diabetes mellitus; HDL, high-density lipoprotein; IDF, International Diabetes Federation; IGT, impaired glucose tolerance;
NCEP ATP III, National Cholesterol Education Program, Adult Treatment Panel III; WHO, World Health Organization.
Ethnic specific cutoffs: South Asians men 90 cm, women 80 cm; Chinese men 90 cm, women 80 cm; Japanese men 85 cm,
women 90 cm (there is no agreement concerning the appropriate cutoff for the Japanese population).

Waist Circumference, Cardiovascular

Disease, and Mortality

Waist Circumference
in the Pediatric Population

The correlation between CVD risk and an increased WC

is well known, although it seems to be less than the correlation between WC and DM. Values for WC are related
to the risk for developing CVD and remain statistically
significant after adjusting for BMI and other cardiovascular risk factors, consistent in men and women.11,36,55-57
All-cause mortality is also related to WC, even when
adjusted for BMI. For any given BMI, an increased
WC confers a higher mortality risk.32,58,59 A recent study
evaluated the association between WC and mortality
among 154,776 men and 90,757 women aged 51 to
72 years at baseline and followed for 9 years. All-cause
mortality was higher in patients with increasing WC,
even when adjusted for BMI and other covariates. Men
with increased WC had a 22% increased mortality risk
and women a 28% increased mortality risk. This finding
was consistent in all races and among smokers and nonsmokers.60

Pediatric obesity is a serious medical problem worldwide.

In the U.S., 19% of children between 6 and 11 years old
are overweight, with BMI greater than the 95th percentile
for their age and sex.61 Cardiometabolic risk factors are
already present in this population (hypertension, dyslipidemia, and impaired glucose tolerance). The use of ageand gender-specific cutoffs (90th percentile) for WC
seems to be a reliable marker for the detection of high-risk
overweight pediatric patients.62 In this population, the use
of WHR (normal 0.5) may be easier in clinical practice
because it does not require age-specific tables.

Ethnicity is known to have on impact on CVD and DM
risk, and because abdominal obesity is a better predictor
of cardiovascular disease than is BMI, the use of ethnicspecific WC seems appropriate. For example, it is known

Downloaded from at NATIONAL SUN YAT-SEN UNIV on August 22, 2014


Nutrition in Clinical Practice / Vol. 23, No. 4, August 2008

that Asians have a higher risk for DM and CVD with

lower BMIs and WC, corresponding to higher VAT for a
given BMI.63-66 African Americans, on the other hand,
have lower VAT compared with Caucasians of the same
BMI and WC.67,68
The IDF has adopted a lower cutoff WC for
Caucasians compared with the NCEP ATP III, corresponding to a BMI of 25 kg/m2, and includes ethnicand gender-specific cutoffs (Table 2). There are still
populations (sub-Saharan Africans, ethnic South and
Central Americans, Eastern Mediterranean, and
Middle East populations) for which ethnic-specific
cutoffs for WC have not been specified; these should
adopt the Caucasian cutoffs for the time being.7

Weight Loss
Weight loss is known to improve insulin resistance, DM
control, hypertension, and lipid profile.69 Lifestyle
changes, including weight loss and physical activity, have
been shown to prevent or delay type 2 DM in high-risk
patients.70,71 In the Diabetes Prevention Program study,
lifestyle intervention was associated with a marked reduction in visceral fat (measured by CT during the first year
of the study) and a smaller decrease in subcutaneous fat,
body weight, BMI, and WC in both men and women.72
Pare et al73 evaluated the change in visceral fat, subcutaneous fat, and waist girth followed by weight loss in obese
men. Their results showed a greater relative reduction in
visceral fat than subcutaneous fat, suggesting greater
mobilization of visceral fat following weight loss in viscerally obese men.
Weight loss achieved through diet and pharmacotherapy with sibutramine, orlistat, and rimonabant
has shown a decrease in WC and improvement in cardiometabolic risk.73-76 Rimonabant therapy has shown a
higher decrease in WC than expected for weight loss, possibly due to its effect on the cannabinoid receptor 1
(CB1) in the VAT.

WC reflects the magnitude of the abdominal fat tissue,
including subcutaneous and visceral adipose tissue.
Although it is a simple and crude measurement, it correlates with VAT and, when increased, has been shown to
confer an increased risk for DM, CVD, and mortality,
independent of BMI. It is now clear that different ethnic
groups should be assessed according to their race-specific
cutoffs to improve risk evaluation. Further study is
needed to specify ethnic-specific WC values. WC measurement should be implemented as a vital sign to improve
cardiometabolic risk assessment.

1. Field AE, Coakley EH, Must A, et al. Impact of overweight on the
risk of developing common chronic diseases during a 10-year
period. Arch Intern Med. 2001;161:1581-1586.
2. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH.
The disease burden associated with overweight and obesity. JAMA.
3. Baskin ML, Ard J, Franklin F, Allison DB. Prevalence of obesity in
the United States. Obes Rev. 2005;6:5-7.
4. Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res. 2002;10(Suppl 2):97S-104S.
5. de Koning L, Merchant AT, Pogue J, Anand SS. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events:
meta-regression analysis of prospective studies. Eur Heart J.
6. Third report of the National Cholesterol Education Program
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults (Adult Treatment Panel III) final
report. Circulation. 2002;106:3143.
7. The IDF consensus worldwide definition of the metabolic syndrome.
Available at:
8. Li C, Ford ES, McGuire LC, Mokdad AH. Increasing trends in
waist circumference and abdominal obesity among U.S. adults.
Obesity. 2007;15:216-224.
9. Ronti T, Lupattelli G, Mannarino E. The endocrine function of
adipose tissue: an update. Clin Endocrinol. 2006;64:355-365.
10. Despres J-P, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881-887.
11. Klein S, Allison DB, Heymsfield SB, et al. Waist circumference
and cardiometabolic risk: a consensus statement from Shaping
Americas Health: Association for Weight Management and
Obesity Prevention; NAASO, The Obesity Society; the American
Society for Nutrition; and the American Diabetes Association.
Diabetes Care. 2007;30:1647-1652.
12. Sinha R, Dufour S, Petersen KF, et al. Assessment of skeletal muscle triglyceride content by 1H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin
sensitivity, total body fat, and central adiposity. Diabetes.
13. Schreuder TC, van Nieuwkerk CM, Mulder CJ. Nonalcoholic fatty
liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol. 2008;14:2474-2486.
14. Thomas EL, Hamilton G, Patel N, et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut.
15. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage
and mobilization in the pathogenesis of insulin resistance and type
2 diabetes. Endocr Rev. 2002;23:201-229.
16. National Institutes of Health. The Practical Guide: Identification,
Evaluation and Treatment of Overweight and Obesity in Adults.
Bethesda, MD: National Institutes of Health; 2000.
17. World Health Organization. Obesity: Preventing and Managing the
Global Epidemic: Report of a WHO Consultation on Obesity.
Geneva, Switzerland: World Health Organization; 1997.
18. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as
a risk factor for clinical diabetes mellitus in women. Ann Intern
Med. 1995;122:481-486.
19. Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med. 1995;333:677-685.
20. Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A,
Bouchard C. Regional distribution of body fat, plasma lipoproteins,
and cardiovascular disease. Arterioscler Thromb Vasc Biol.

Downloaded from at NATIONAL SUN YAT-SEN UNIV on August 22, 2014

Waist Circumference Measurement / Ness-Abramof, Apovian

21. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths
associated with underweight, overweight, and obesity. JAMA.
22. Tanko LB, Bagger YZ, Alexandersen P, Larsen PJ, Christiansen C.
Peripheral adiposity exhibits an independent dominant antiatherogenic effect in elderly women. Circulation. 2003;107:1626-1631.
23. Bjorntorp P. Obesity. Lancet. 1997;350:423-426.
24. Wannamethee SG, Shaper AG, Morris RW, Whincup PH.
Measures of adiposity in the identification of metabolic abnormalities in elderly men. Am J Clin Nutr. 2005;81:1313-1321.
25. Wannamethee SG, Shaper AG, Lennon L, Whincup PH.
Decreased muscle mass and increased central adiposity are independently related to mortality in older men. Am J Clin Nutr.
26. Woo J, Ho SC, Yu ALM, Sham L. Is waist circumference a useful
measure in predicting health outcomes in the elderly? Int J Obes.
27. Despres JP. The insulin resistance-dyslipidemic syndrome of visceral
obesity: effect on patients risk. Obesity Res. 1998;6(Suppl 1):8S-17S.
28. Han TS, van Leer EM, Seidell JC, Lean MEJ. Waist circumference
action levels in the identification of cardiovascular risk factors:
prevalence study in a random sample. BMJ. 1995;311:1401-1405.
29. Lean MEJ, Han TS, Morrison CE. Waist circumference as a measure
for indicating need for weight management. BMJ. 1995;311:158-161.
30. Shen W, Punyanitya M, Chen J, et al. Waist circumference correlates with metabolic syndrome indicators better than percentage
fat. Obesity. 2006;14:727-736.
31. Definition, Diagnosis and Classification of Diabetes Mellitus and Its
Complications: Report of a WHO Consultation. Geneva, Switzerland:
Department of Noncommunicable Disease Surveillance, World
Health Organization; 1999.
32. Larsson B, Svrdsudd K, Welin L, Wilhelmsen L, Bjrntorp P,
Tibblin G. Abdominal adipose tissue distribution, obesity, and risk
of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. BMJ (Clin Res Ed).
33. Ohlson LO, Larsson B, Svrdsudd K, et al. The influence of body
fat distribution on the incidence of diabetes mellitus: 13.5 years of
follow-up of the participants in the study of men born in 1913.
Diabetes. 1985;34:1055-1058.
34. Dalton M, Cameron AJ, Zimmet PZ, et al. Waist circumference,
waist-hip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults. J Intern Med.
35. Pouliot MC, Despres JP, Lemieux S, et al. Waist circumference
and abdominal sagittal diameter: best simple anthropometric
indexes of abdominal visceral adipose tissue accumulation and
related cardiovascular risk in men and women. Am J Cardiol.
36. Yusuf S, Hawken S, Ounpuu S; INTERHEART Study Investigators.
Obesity and the risk of myocardial infarction in 27,000 participants
from 52 countries: a case-control study. Lancet. 2005;366:1640-1649.
37. Ross R, Berentzen T, Bradshaw AJ, et al. Does the relationship
between waist circumference, morbidity and mortality depend on
measurement protocol for waist circumference? Obes Rev.
38. Ahima RS. Adipose tissue as an endocrine organ. Obesity. 2006;
14(Suppl 4):242S-249S.
39. Shen W, Wang Z, Punyanita M, et al. Adipose tissue quantification
by imaging methods: a proposed classification. Obes Res.
40. Jensen MD. Is visceral fat involved in the pathogenesis of the metabolic syndrome? Human Model Obes. 2006;14(Suppl 1):20S-24S.
41. Lemieux I, Pascot A, Prudhomme D, et al. Elevated C-reactive
protein: another component of the atherothrombotic profile of
abdominal obesity. Arterioscler Thromb Vasc Biol. 2001;21:961-967.


42. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive
protein in cardiovascular risk prediction models for women. Ann
Intern Med. 2006;145:21-29.
43. Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J Clin
Invest. 2006;116:33-35.
44. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral
fat adipokine secretion is associated with systemic inflammation in
obese humans. Diabetes. 2007;56:1010-1013.
45. Scherer PE. Adipose tissue: from lipid storage compartment to
endocrine organ. Diabetes. 2006;55:1537-1545.
46. Cote M, Mauriege P, Bergeron J, et al. Adiponectinemia in visceral
obesity: impact on glucose tolerance and plasma lipoprotein and
lipid levels in men. J Clin Endocrinol Metab. 2005;90:1434-1439.
47. Menzaghi C, Trischitta V, Doria A. Genetic influences of
adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes. 2007;56:1198-1209.
48. Rask E, Walker BR, Soderberg S, et al. Tissue-specific changes in
peripheral cortisol metabolism in obese women: increased adipose 11
-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol
Metab. 2002;87:3330-3336.
49. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart
Association/National Heart, Lung, and Blood Institute scientific
statement. Circulation. 2005;112:2735-2752.
50. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation:
a consensus on type 2 diabetes prevention. Diabetic Med. 2007;24:
51. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome:
time for a critical appraisal Joint statement from the American
Diabetes Association and the European Association for the Study
of Diabetes. Diabetes Care. 2005;28:2289-2304.
52. Grundy SM. Does the metabolic syndrome exist? Diabetes Care.
53. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes,
impaired fasting glucose, and impaired glucose tolerance in U.S.
adults. The Third National Health and Nutrition Examination
Survey, 1988-1994. Diabetes Care. 1998;21:518-524.
54. Balkau B, Deanfield JE, Desprs JP, et al. International Day for the
Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000
primary care patients in 63 countries. Circulation. 2007;116:1942-1951.
55. Rexrode KM, Buring JE, Manson JE. Abdominal and total adiposity and risk of coronary heart disease in men. Int J Obes Relat
Metab Disord. 2001;25:1047-1056.
56. Freiberg MS, Pencina MJ, DAgostino RB, Lanier K, Wilson PWF,
Vasan RS. BMI vs. waist circumference for identifying vascular
risk. Obesity. 2008;16:463-469.
57. Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity
and coronary heart disease in women. JAMA. 1998;280:1843-1848.
58. Bigaard J, Tjonneland A, Thomsen BL, Overvad K, Heitmann BL,
Sorensen TIA. Waist circumference, BMI, smoking, and mortality
in middle-aged men and women. Obes Res. 2003;11:895-903.
59. Katzmarzyk PT, Janssen I, Ross R, Church TS, Blair SN. The
importance of waist circumference in the definition of metabolic
syndrome: prospective analyses of mortality in men. Diabetes Care.
60. Koster A, Leitzmann MF, Schatzkin A, et al. Waist circumference
and mortality. Am J Epidemiol. 2008;167:1465-1475.
61. Dietz WH, Robinson TN. Overweight children and adolescents. N
Engl J Med. 2005;352:2100-2109.
62. Claudio M, Claudia B, Giorgio T. Waist-to-height ratio, a useful
index to identify high metabolic risk in overweight children. J
Pediatr. 2008;152:207-213.
63. WHO Expert Consultation. Appropriate body-mass index for Asian
populations and its implications for policy and intervention strategies. Lancet. 2004;363:157-163.

Downloaded from at NATIONAL SUN YAT-SEN UNIV on August 22, 2014


Nutrition in Clinical Practice / Vol. 23, No. 4, August 2008

64. Deurengerg-Yap M, Schmidt G, van Staveren WA, Deurenberg P.

The paradox of low body mass index and high body fat percentage
among Chinese, Malays and Indians in Singapore. Int J Obes Relat
Metab Disord. 2000;24:1011-1017.
65. Razak F, Anand SS, Shannon H, et al. Defining obesity cut points
in a multiethnic population. Circulation. 2007;115:2111-2118.
66. Scott AL, Mustafa T, Birmingham CL, Jiri JF. Modification of the
relationship between simple anthropometric indices and risk factors by ethnic background. Metabolism. 2003;52:1295-1301.
67. Carroll JF, Chiapa AL, Rodriquez M, et al. Visceral fat, waist
circumference, and BMI: impact of race/ethnicity. Obesity.
68. Zhu S, Heymsfield SB, Toyoshima H, Wang Z, Pietrobelli A,
Heshka S. Race-ethnicity-specific waist circumference cutoffs for
identifying cardiovascular disease risk factors. Am J Clin Nutr.
69. Clinical guidelines on the identification, evaluation, and treatment
of overweight and obesity in adults: the Evidence Report. Natl Inst
Health Obes Res. 1998;6(Suppl 2):51S-209S.
70. Tuomilehto J, Lindstrom J, Eriksson JG, et al; the Finnish Diabetes
Prevention Study Group. Prevention of type 2 diabetes mellitus by
changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.

71. Diabetes Prevention Program Research Group. Reduction in the

incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
72. Fujimoto WY, Jablonski KA, Bray GA, et al, for the Diabetes
Prevention Program Research Group. Body size and shape changes
and the risk of diabetes in the diabetes prevention program.
Diabetes. 2007;56:1680-1685.
73. Pare A, Dumont M, Lemieux I, et al. Is the relationship between
adipose tissue and waist girth altered by weight loss in obese men?
Obes Res. 2001;9:526-534.
74. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight
maintenance after weight loss: a randomised trial. STORM Study
Group. Sibutramine Trial of Obesity Reduction and Maintenance.
Lancet. 2000;356:2119-2125.
75. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G.
Weight loss, weight maintenance, and improved cardiovascular
risk factors after 2 years treatment with orlistat for obesity. Obes
Res. 2000;8:49-61.
76. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J,
for the RIONASG: Effect of rimonabant, a cannabinoid-1 receptor
blocker, on weight and cardiometabolic risk factors in overweight
or obese patients: RIO-North America: a randomized controlled
trial. JAMA. 2006;295:761-775.

Downloaded from at NATIONAL SUN YAT-SEN UNIV on August 22, 2014